Therapeutic Solutions International, Inc. (TSOI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.01 Million USD | -9.48% |
| 2022 | 2.22 Million USD | -11.9% |
| 2021 | 2.52 Million USD | 5.84% |
| 2020 | 2.38 Million USD | 1.51% |
| 2019 | 2.34 Million USD | 16.29% |
| 2018 | 2.01 Million USD | 50.45% |
| 2017 | 1.34 Million USD | 76.5% |
| 2016 | 759.7 Thousand USD | 55.36% |
| 2015 | 488.99 Thousand USD | 47.06% |
| 2014 | 332.5 Thousand USD | -57.71% |
| 2013 | 786.19 Thousand USD | 99.31% |
| 2012 | 394.45 Thousand USD | -87.5% |
| 2011 | 3.15 Million USD | 11185.56% |
| 2010 | 27.96 Thousand USD | 116.85% |
| 2009 | 12.89 Thousand USD | 77.89% |
| 2008 | 7250.00 USD | 36.53% |
| 2007 | 5310.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.04 Million USD | 1.62% |
| 2024 Q2 | 1.93 Million USD | -5.06% |
| 2023 FY | 2.01 Million USD | -9.48% |
| 2023 Q4 | 2.01 Million USD | -7.16% |
| 2023 Q1 | 2.38 Million USD | 7.39% |
| 2023 Q2 | 1.99 Million USD | -16.29% |
| 2023 Q3 | 2.16 Million USD | 8.46% |
| 2022 Q2 | 2.32 Million USD | -5.94% |
| 2022 Q3 | 2.4 Million USD | 3.42% |
| 2022 Q4 | 2.22 Million USD | -7.8% |
| 2022 Q1 | 2.47 Million USD | -1.77% |
| 2022 FY | 2.22 Million USD | -11.9% |
| 2021 Q3 | 2.28 Million USD | 7.75% |
| 2021 FY | 2.52 Million USD | 5.84% |
| 2021 Q2 | 2.12 Million USD | -8.22% |
| 2021 Q4 | 2.52 Million USD | 10.22% |
| 2021 Q1 | 2.31 Million USD | -2.9% |
| 2020 Q3 | 2.01 Million USD | -3.45% |
| 2020 Q4 | 2.38 Million USD | 18.27% |
| 2020 Q1 | 2.25 Million USD | -3.71% |
| 2020 FY | 2.38 Million USD | 1.51% |
| 2020 Q2 | 2.08 Million USD | -7.68% |
| 2019 Q1 | 1.92 Million USD | -4.54% |
| 2019 Q4 | 2.34 Million USD | 19.68% |
| 2019 Q2 | 1.85 Million USD | -3.88% |
| 2019 Q3 | 1.96 Million USD | 5.89% |
| 2019 FY | 2.34 Million USD | 16.29% |
| 2018 Q2 | 1.9 Million USD | 29.51% |
| 2018 Q3 | 1.7 Million USD | -10.62% |
| 2018 Q4 | 2.01 Million USD | 18.45% |
| 2018 FY | 2.01 Million USD | 50.45% |
| 2018 Q1 | 1.47 Million USD | 9.73% |
| 2017 Q3 | 1.18 Million USD | 16.16% |
| 2017 Q4 | 1.34 Million USD | 13.17% |
| 2017 FY | 1.34 Million USD | 76.5% |
| 2017 Q2 | 1.02 Million USD | 23.78% |
| 2017 Q1 | 824.07 Thousand USD | 8.47% |
| 2016 Q4 | 759.7 Thousand USD | 24.18% |
| 2016 Q3 | 611.79 Thousand USD | 15.22% |
| 2016 Q1 | 491.79 Thousand USD | 0.57% |
| 2016 FY | 759.7 Thousand USD | 55.36% |
| 2016 Q2 | 530.99 Thousand USD | 7.97% |
| 2015 FY | 488.99 Thousand USD | 47.06% |
| 2015 Q4 | 488.99 Thousand USD | 46.4% |
| 2015 Q3 | 334.01 Thousand USD | 5.63% |
| 2015 Q2 | 316.21 Thousand USD | -5.1% |
| 2015 Q1 | 333.2 Thousand USD | 0.21% |
| 2014 Q2 | 588.13 Thousand USD | -25.13% |
| 2014 Q1 | 785.48 Thousand USD | -0.09% |
| 2014 FY | 332.5 Thousand USD | -57.71% |
| 2014 Q4 | 332.5 Thousand USD | -18.98% |
| 2014 Q3 | 410.41 Thousand USD | -30.22% |
| 2013 Q2 | 681.57 Thousand USD | 23.29% |
| 2013 Q4 | 786.19 Thousand USD | 2.63% |
| 2013 Q1 | 552.82 Thousand USD | 40.15% |
| 2013 FY | 786.19 Thousand USD | 99.31% |
| 2013 Q3 | 766.07 Thousand USD | 12.4% |
| 2012 Q1 | 3.12 Million USD | -0.92% |
| 2012 Q3 | 220.19 Thousand USD | -93.32% |
| 2012 Q4 | 394.45 Thousand USD | 79.14% |
| 2012 FY | 394.45 Thousand USD | -87.5% |
| 2012 Q2 | 3.29 Million USD | 5.41% |
| 2011 Q2 | 3.15 Million USD | 4498.09% |
| 2011 FY | 3.15 Million USD | 11185.56% |
| 2011 Q4 | 3.15 Million USD | 1.34% |
| 2011 Q1 | 68.62 Thousand USD | 145.38% |
| 2011 Q3 | 3.11 Million USD | -1.29% |
| 2010 Q3 | 24.9 Thousand USD | 5.96% |
| 2010 Q4 | 27.96 Thousand USD | 12.31% |
| 2010 Q1 | 17.31 Thousand USD | 34.27% |
| 2010 FY | 27.96 Thousand USD | 116.85% |
| 2010 Q2 | 23.5 Thousand USD | 35.72% |
| 2009 Q3 | 17.94 Thousand USD | 19.97% |
| 2009 Q4 | 12.89 Thousand USD | -28.12% |
| 2009 Q2 | 14.95 Thousand USD | 106.29% |
| 2009 Q1 | 7250.00 USD | 0.0% |
| 2009 FY | 12.89 Thousand USD | 77.89% |
| 2008 Q4 | 7250.00 USD | 389.86% |
| 2008 FY | 7250.00 USD | 36.53% |
| 2008 Q2 | 5310.00 USD | 0.0% |
| 2008 Q3 | 1480.00 USD | -72.13% |
| 2008 Q1 | 5310.00 USD | 0.0% |
| 2007 FY | 5310.00 USD | 0.0% |
| 2007 Q4 | 5310.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -7227.416% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 78.765% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 97.226% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -148.534% |
| Rebus Holdings, Inc. | 5.24 Million USD | 61.653% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 96.594% |
| Qrons Inc. | 1.48 Million USD | -35.025% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -63.93% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 97.317% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -4397.338% |
| Skye Bioscience, Inc. | 14.07 Million USD | 85.716% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 96.229% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 79.022% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -376.822% |
| SQZ Biotechnologies Company | 50.03 Million USD | 95.983% |
| Intellipharmaceutics International Inc. | 12 Million USD | 83.261% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 47.808% |
| Mesoblast Limited | 188.44 Million USD | 98.933% |
| Marizyme, Inc. | 26.67 Million USD | 92.465% |
| Genus plc | 485 Million USD | 99.586% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 65.595% |
| Pharming Group N.V. | 244.07 Million USD | 99.176% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 20.117% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 47.102% |
| ContraFect Corporation | 32.53 Million USD | 93.821% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -1.455% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 47.484% |
| IMV Inc. | 37.93 Million USD | 94.701% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 82.933% |
| MultiCell Technologies, Inc. | 1617.67 USD | -124160.82% |
| ONE Bio Corp. | 27.49 Million USD | 92.689% |
| Accustem Sciences Inc. | 1.07 Million USD | -86.254% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 97.404% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 4.961% |
| Q BioMed Inc. | 8.13 Million USD | 75.284% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 97.576% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 60.938% |
| Biomind Labs Inc. | 1.49 Million USD | -34.133% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.307% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 77.769% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 89.077% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -40.19% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1314.638% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -899.488% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 65.016% |
| GB Sciences, Inc. | 5.41 Million USD | 62.896% |
| Alpha Cognition Inc. | 7.16 Million USD | 71.944% |
| HST Global, Inc. | 593.59 Thousand USD | -238.638% |
| CSL Limited | 18.62 Billion USD | 99.989% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -59.636% |
| Halberd Corporation | 728.71 Thousand USD | -175.844% |
| Enzolytics Inc. | 365.26 Million USD | 99.45% |
| Agentix Corp. | 2.51 Million USD | 19.933% |
| Resverlogix Corp. | 67.39 Million USD | 97.017% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -139.663% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.548% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -17.277% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 91.877% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 83.113% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 45.156% |
| AVAX Technologies, Inc. | 3.99 Million USD | 49.668% |
| Zenith Capital Corp. | 27.56 Thousand USD | -7191.269% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.848% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -742.278% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 46.171% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -195.245% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 25.87% |
| Kadimastem Ltd | 3.5 Million USD | 42.647% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -2903.377% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 96.001% |
| BioStem Technologies, Inc. | 15.9 Million USD | 87.361% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -332.566% |
| LadRx Corporation | 2.2 Million USD | 8.652% |
| Cell Source, Inc. | 15.8 Million USD | 87.283% |
| Regen BioPharma, Inc. | 5.45 Million USD | 63.168% |
| Regen BioPharma, Inc. | 5.45 Million USD | 63.168% |
| NovAccess Global Inc. | 7.86 Million USD | 74.428% |
| Affymax, Inc. | 8.87 Million USD | 77.34% |
| Itoco Inc. | 1.65 Million USD | -21.594% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 2.02% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 66.769% |
| Mobile Lads Corp. | 1.31 Million USD | -53.037% |
| CytoDyn Inc. | 127.89 Million USD | 98.428% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -4709.038% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -28.33% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 81.801% |
| SYBLEU INC | 681.41 Thousand USD | -194.994% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 67.057% |
| International Stem Cell Corporation | 5.27 Million USD | 61.908% |
| Bioxytran, Inc. | 3.24 Million USD | 38.14% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -221.205% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 56.464% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 95.097% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 90.972% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 0.753% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 63.305% |
| Neutra Corp. | 973.52 Thousand USD | -106.479% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 93.072% |
| PureTech Health plc | 125.58 Million USD | 98.399% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 46.498% |
| IXICO plc | 1.9 Million USD | -5.78% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 90.208% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.055% |
| CSL Limited | 18.62 Billion USD | 99.989% |
| Cellectis S.A. | 249.36 Million USD | 99.194% |